Multivax P Plus

Indications

• Prevention of blackleg in cattle
• Prevention of blackleg in sheep

Dosage

Children: Refer to veterinary guidelines for specific dosing recommendations, as doses can vary based on the formulation and route of administration.

Adults: Refer to veterinary guidelines for specific dosing recommendations, as doses can vary based on the formulation and route of administration.

Mechanism of action

Clostridium chauvoei produces a range of toxins, including alpha-toxin, which is a phospholipase that damages host cell membranes, leading to cell lysis and tissue necrosis. The toxins disrupt normal cellular function and promote inflammation, contributing to the clinical manifestations of the disease.

Pharmacodynamics

The primary pharmacodynamic action of Chauvoei is the induction of necrotizing myositis and systemic toxicity through the production of its virulence factors. The release of toxins into the bloodstream can cause fever, shock, and, in severe cases, death. The disease is characterized by sudden onset, rapid progression, and a high mortality rate if not treated promptly.

Pharmacokinetics

The pharmacokinetics of Chauvoei are not typically studied in the same manner as traditional pharmaceuticals, given that it is a bacterium rather than a medication. However, once the spores are introduced into the host, they germinate in anaerobic conditions, multiply rapidly, and produce toxins, resulting in the clinical disease. The immune response may help to clear the infection, but in severe cases, the disease progresses rapidly, necessitating immediate veterinary intervention.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering to breastfeeding mothers, as safety is not established.

Storage

Store in a cool, dry place away from light. Protect from freezing.

Formulations

• Injectable solution

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Sepsis

Dosage

Children: Refer to the BNF for Children for age-appropriate dosing guidelines based on the specific antibiotic and clinical scenario.

Adults: Refer to specific antibiotic guidelines based on culture and sensitivity results, as well as the severity of the infection.

Mechanism of action

The mechanism of action of antibiotics used to treat infections caused by haemolytica involves inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, depending on the specific antibiotic. For instance, beta-lactam antibiotics target penicillin-binding proteins, disrupting cell wall formation, leading to cell death.

Pharmacodynamics

Pharmacodynamics of antibiotics against haemolytica involves their ability to inhibit bacterial growth (bacteriostatic) or kill bacteria (bactericidal), depending on the drug class. The efficacy of these agents is often evaluated based on their minimum inhibitory concentration (MIC) and their ability to achieve therapeutic concentrations at the site of infection.

Pharmacokinetics

Pharmacokinetics of antibiotics vary widely but generally encompass absorption, distribution, metabolism, and excretion (ADME) profiles. Many antibiotics are rapidly absorbed in the gastrointestinal tract, distributed widely in body tissues, and are excreted primarily via the kidneys. Half-lives can vary significantly, influencing dosing frequency.

Pregnancy

There is limited data on the use of haemolytica in pregnancy. Caution is advised, and it should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

There is insufficient information regarding the safety of haemolytica during breastfeeding. Caution is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Ensure it is kept out of reach of children.

Indications

• Bovine respiratory disease complex
• Ovine pneumonia
• Systemic infections in livestock

Dosage

Children: Refer to veterinary guidelines for appropriate dosing based on the specific antibiotic used and the severity of the infection.

Adults: Refer to veterinary guidelines for appropriate dosing based on the specific antibiotic used and the severity of the infection.

Mechanism of action

Mannheimia haemolytica produces several virulence factors, including leukotoxin, which targets and kills neutrophils, leading to immune system evasion. The bacterium also produces various enzymes and toxins that contribute to tissue damage and inflammation, promoting disease progression.

Pharmacodynamics

The pharmacodynamics of treatment against Mannheimia involve the use of antibiotics and anti-inflammatory agents. Antibiotics target the bacterial cell wall synthesis or protein synthesis, leading to bacterial cell death or growth inhibition. Anti-inflammatory drugs help mitigate the inflammatory response caused by the infection, reducing clinical signs and improving recovery rates in affected animals.

Pharmacokinetics

The pharmacokinetics of antibiotics effective against Mannheimia, such as tetracyclines or macrolides, vary based on the specific drug used. Generally, these agents are well-absorbed after administration, widely distributed throughout body tissues, and eliminated by renal or hepatic pathways. The half-life and duration of action depend on the specific antibiotic characteristics and the route of administration.

Pregnancy

There is limited data on the use of Mannheimia during pregnancy. Caution is advised when prescribing.

Breast-feeding

Safety during breastfeeding is not well established. Caution is recommended.

Storage

Store at room temperature, away from direct sunlight and moisture.

Dosage

Children: Dosing information for paediatric populations is not established. Consult relevant pediatric dosing guidelines and clinical resources as data emerges.

Adults: Dosing information for adults is not yet established. Clinical trials and studies are ongoing to determine appropriate dosing regimens. Refer to official guidelines as they become available.

Mechanism of action

The precise mechanism of action for Novyi is not fully elucidated, but it is believed to interact with specific molecular targets in the body, potentially modulating biological pathways that influence disease states. Further research is necessary to clarify its pharmacological effects and the specific receptors or enzymes it may affect.

Pharmacodynamics

Novyi exhibits a range of pharmacodynamic activities which are under investigation. Early studies suggest that it may influence cellular signaling pathways, alter gene expression, or have effects on neurotransmission or immune responses. The full extent of its pharmacodynamic profile is still under research.

Pharmacokinetics

The pharmacokinetics of Novyi, including absorption, distribution, metabolism, and excretion (ADME), is currently being studied. Initial findings suggest variable bioavailability, with ongoing assessments to determine its half-life and potential interactions with other drugs. Understanding its pharmacokinetic properties is crucial in defining appropriate dosing regimens.

Pregnancy

The safety of novyi during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if novyi is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Gas gangrene
• Clostridial myonecrosis
• Food poisoning
• Soft tissue infections

Dosage

Children: Refer to specific antibiotic guidelines for dosing as it varies by drug choice and severity of the infection.

Adults: Refer to specific antibiotic guidelines for dosing as it varies by drug choice and severity of the infection.

Mechanism of action

Clostridium perfringens produces several toxins, including alpha-toxin (lecithinase), which disrupts cell membranes and promotes tissue destruction. The toxins act on phospholipids in cell membranes, leading to cell lysis and necrosis. Additionally, the bacterium's ability to produce gas (hydrogen and carbon dioxide) contributes to tissue swelling and further compromises blood flow.

Pharmacodynamics

The pharmacodynamics of antibiotics used against Clostridium perfringens involve the inhibition of bacterial cell wall synthesis (for beta-lactams), disruption of protein synthesis (for aminoglycosides and tetracyclines), or interference with nucleic acid synthesis (for fluoroquinolones). The effectiveness of these antibiotics can vary based on the specific strain and its susceptibility profile.

Pharmacokinetics

Pharmacokinetic properties depend on the specific antibiotic used to treat Clostridium perfringens infections. Generally, antibiotics may have varying absorption rates, distribution volumes, half-lives, and elimination routes, which can influence their dosing and effectiveness in treating infections caused by this organism.

Pregnancy

Perfringens is not typically used as a medication but is related to Clostridium perfringens, which is associated with foodborne illness. Consult healthcare providers for guidance during pregnancy.

Breast-feeding

Due to the lack of specific medicinal use, consult healthcare providers for advice regarding breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. If used in a laboratory context, follow specific biosafety guidelines.

Indications

• Bacterial infections
• Pneumonia
• Skin and soft tissue infections
• Urinary tract infections
• Bone and joint infections

Dosage

Children: Dosing for paediatric patients should be determined based on age, weight, and specific clinical guidelines. Refer to appropriate pediatric dosing references for detailed guidance.

Adults: Dosage varies based on the type and severity of infection. Refer to established clinical guidelines for specific dosing regimens.

Mechanism of action

Septicum works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, disrupting the cross-linking of peptidoglycan layers, which is essential for bacterial cell wall structural integrity.

Pharmacodynamics

The pharmacodynamics of Septicum involve the relationship between its concentration and the effect on bacterial growth and survival. It exhibits time-dependent killing, meaning that its efficacy is related to the duration of time that the drug concentration remains above the minimum inhibitory concentration (MIC) for the target organism. Bacterial resistance can develop, particularly with prolonged use or in immunocompromised patients.

Pharmacokinetics

Septicum is absorbed well from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. It is widely distributed throughout body tissues and fluids, with a volume of distribution that suggests extensive tissue penetration. The drug is primarily excreted unchanged in the urine, and its half-life is approximately 1 to 2 hours in individuals with normal renal function. Dosing adjustments may be necessary in patients with renal impairment.

Pregnancy

The effects of septicum during pregnancy are not well studied. It should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether septicum is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Tetanus prophylaxis in unimmunized individuals
• Management of active tetanus infection
• Prevention of tetanus in surgical procedures

Dosage

Adults: Refer to specific guidelines for tetanus immunization and management of active

Mechanism of action

The primary mechanism of action of tetanospasmin, the toxin produced by Clostridium tetani, involves the inhibition of neurotransmitter release at inhibitory synapses in the central nervous system. It prevents the release of glycine and gamma-aminobutyric acid (GABA), neurotransmitters that are crucial for muscle relaxation. This leads to unopposed excitation of motor neurons, resulting in the characteristic muscle spasms and rigidity associated with tetanus.

Pharmacodynamics

The pharmacodynamics of tetanospasmin involve its interaction with the nervous system, particularly at the spinal cord level. Once the toxin enters the bloodstream and binds to peripheral nerves, it retrogradely transports to the spinal cord, where it interferes with inhibitory pathways. This disruption leads to hyperexcitability of motor neurons, causing sustained muscle contractions and spasms. The severity of symptoms can vary based on the amount of toxin produced and the individual's immune response.

Pharmacokinetics

The pharmacokinetics of the tetanospasmin toxin are complex, as it is not a conventional drug with defined pharmacokinetic parameters. After release into the body, the toxin binds rapidly to nerve endings and is taken up into motor neurons. The onset of symptoms typically occurs within 7 to 14 days after infection, although it can vary. The half-life of the toxin is not well-defined due to its irreversible binding properties and the body's subsequent immune response to the toxin. The duration of the clinical effects can last from several days to weeks, depending on the severity of the infection and the treatment administered.

Pregnancy

There is limited data on the use of tetani during pregnancy. Consult clinical guidelines and consider risk versus benefit.

Breast-feeding

Consult clinical guidelines. Use with caution and consider risk versus benefit when breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions as per the manufacturer's guidelines.

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid